Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/ASTRAZEN stock hub

NSE/ASTRAZEN has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/ASTRAZENis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

212.2B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/ASTRAZEN

In the news

Latest news · NSE/ASTRAZEN

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E105.6

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC42.1

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/ASTRAZEN market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

197

Groups with data

Currency

INR

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	600
Employees Change	-200%
Employees Change Percent	-25
Enterprise value	INR 208.6B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE203A01020
Last refreshed	2026-05-10
Market cap	INR 212.2B
Price	INR 8,500
Price currency	INR
Rev Per Employee	36,290,833.33x
Sector	Healthcare
Sic	2834
Symbol	nse/ASTRAZEN
Website	https://www.astrazeneca.in

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.95%
EV Earnings	103.83x
EV/EBIT	84.22x
EV/EBITDA	68.92x
EV/Sales	9.58x
P/B ratio	26.56x
P/E ratio	105.65x
P/S ratio	9.75x
PE Ratio10 Y	133.47x
PE Ratio3 Y	127.87x
PE Ratio5 Y	115.78x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.37%
EBITDA Margin	13.67%
Gross margin	42.52%
Gross Profit	INR 9.3B
Gross Profit Growth	33.05%
Gross Profit Growth Q	26.87%
Gross Profit Growth3 Y	15.79%
Gross Profit Growth5 Y	13.4%
Net Income	INR 2B
Net Income Growth	107.17%
Net Income Growth Q	5.64%
Net Income Growth Quarters	5%
Net Income Growth Years	0%
Net Income Growth3 Y	22.23%
Net Income Growth5 Y	21.59%
Pretax Margin	12.52%
Profit Margin	9.23%
Profit Per Employee	INR 3.3M
Profitable Years	10
Roa5y	9.19
Roe5y	18.8
ROIC	42.08
Roic5y	81.27

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	22.43%
Cagr15y	13.48%
Cagr1y	4.16%
Cagr20y	12.91%
Cagr3y	38.86%
Cagr5y	17.75%
Div CAGR10	41.42%
Div CAGR3	25.99%
Div CAGR5	74.11%
EPS Growth	107.3
EPS Growth Q	5.67
EPS Growth Quarters	5
EPS Growth Years	0
EPS Growth3 Y	22.23
EPS Growth5 Y	21.59
Revenue Growth	34.49x
Revenue Growth Q	38.9x
Revenue Growth Quarters	17x
Revenue Growth Years	3x
Revenue Growth3 Y	31.84x
Revenue Growth5 Y	22.23x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 4B
Debt	INR 347.9M
Debt EBITDA	INR 0.11
Debt Equity	INR 0.04
Equity	INR 8B
Interest Coverage	79.12
Net Cash	INR 3.7B
Net Cash By Market Cap	INR 1.72
Net Cash Growth	-23.87%
Net Debt EBITDA	INR -1.23
Net Debt Equity	INR -0.46
Tangible Book Value	INR 8B
Tangible Book Value Per Share	INR 320
WACC	5.56

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.04%
Dividend Growth	33.33%
Dividend Growth Years	4%
Dividend per share	INR 32
Dividend Years	7
Dividend Yield	0.38%
Ex Div Date	2025-07-18
Last Dividend	INR 32
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	656.29%
1Y total return	4.15%
200-day SMA	8,794.9
3Y total return	167.82%
50-day SMA	8,424.3
50-day SMA vs 200-day SMA	50under200
5Y total return	126.35%
All Time High	10,691
All Time High Change	-20.49%
All Time High Date	2025-06-13
All Time Low	29.7
All Time Low Change	28,519.53%
All Time Low Date	1998-07-30
ATR	243.9
Beta	0.24
Ch YTD	-5.86
High	8,670.5
High52	10,691
High52 Date	2025-06-13
High52ch	-20.49%
Low	8,452.5
Low52	7,551.5
Low52 Date	2026-04-06
Low52ch	12.56%
Ma50ch	0.9%
Price vs 200-day SMA	-3.35%
RSI	54.05
RSI Monthly	56.08
RSI Weekly	47.61
Sharpe ratio	-0.05x
Sortino ratio	0.14
Total Return	0.42%
Tr YTD	-5.86
Tr15y	566.2%
Tr1m	9.09%
Tr1w	5.64%
Tr3m	-1.16%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 2.5B
Operating Income Growth	28.42
Operating Income Growth Q	-39.65
Operating Income Growth3 Y	24.95
Operating Income Growth5 Y	22.04
Operating margin	11.37

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4,604,421%
Shares Insiders	6.18%
Shares Institutions	8.21%
Shares Qo Q	-0.02%
Shares Yo Y	-0.04%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	9,989.9x
Bv Per Share	319.6
Ch10y	644.6
Ch15y	549.6
Ch1m	9.09
Ch1w	5.64
Ch1y	3.8
Ch20y	913.1
Ch3m	-1.16
Ch3y	164.9
Ch5y	123.1
Ch6m	-6.36
Change	-0.57%
Change From Open	-0.45
Close	8,549
Days Gap	-0.13
Depreciation Amortization	500,625,000
Dollar Volume	35,300,500
Earnings Date	2026-05-30
EBIT	INR 2.5B
EBITDA	INR 3B
EPS	INR 80.38
F Score	1
Fiscal Year End	March
Founded	1,979
Graham Number	761.12047
Graham Upside	-91.05
Income Tax	INR 716.4M
Is Primary Listing	0
Last Earnings Date	2026-02-11
Last Report Date	2025-12-31
Lynch Fair Value	INR 1,737
Lynch Upside	-79.57
Ma150	8,776.5
Ma150ch	-3.15%
Ma20	8,417.9
Ma20ch	0.98%
Next Earnings Date	2026-05-30
Open	8,538
Payment Date	2025-09-12
Position In Range	21.79
Price Date	2026-05-08
Price EBITDA	INR 71.29
Ptbv Ratio	26.56
Relative Volume	0.41x
Revenue	21,774,500,000x
Tax By Revenue	3.29x
Tax Rate	26.29%
Tr20y	1,033.47%
Tr6m	-6.36%
Volume	4,153

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/ASTRAZEN dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.4%

$32.0 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+74.1%

4 consecutive years of growth

Total shareholder yield

+0.4%

Next ex-dividend date: 2025-07-18

Performance

NSE/ASTRAZEN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/ASTRAZEN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+8.2%

Share of float held by funds and institutions

Insider ownership

+6.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.0%

Negative means the company is buying back shares.

Technical

NSE/ASTRAZEN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.1

Neutral momentum band

Price vs 200-day MA

-3.4%

50/200-day relationship not available

Beta (5Y)

0.24

Less volatile than the market

Sharpe ratio

-0.05

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/ASTRAZEN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/ASTRAZEN stock rating?

nse/ASTRAZEN is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/ASTRAZEN analysis?

The full report lives at /stocks/nse/ASTRAZEN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/ASTRAZEN?

The latest report frames nse/ASTRAZEN around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/ASTRAZEN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.